Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $730,450.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at $5,993,989.22. This trade represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 18th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00.
• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total transaction of $782,556.25.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $37.02 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The stock’s 50 day simple moving average is $45.41 and its 200-day simple moving average is $41.01. The company has a market cap of $2.34 billion, a PE ratio of -14.18 and a beta of 1.15. Vera Therapeutics, Inc. has a 1-year low of $14.20 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on VERA shares. Wells Fargo & Company initiated coverage on Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. Guggenheim boosted their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Scotiabank started coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 target price for the company. Finally, Wedbush increased their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $63.50.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Holocene Advisors LP raised its holdings in Vera Therapeutics by 8.8% in the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock valued at $86,390,000 after acquiring an additional 158,451 shares during the last quarter. Samlyn Capital LLC grew its position in shares of Vera Therapeutics by 90.8% in the second quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after purchasing an additional 586,410 shares in the last quarter. First Light Asset Management LLC increased its holdings in shares of Vera Therapeutics by 130.6% in the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares during the last quarter. Geode Capital Management LLC lifted its position in Vera Therapeutics by 2.1% during the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock worth $44,415,000 after buying an additional 20,223 shares in the last quarter. Finally, Logos Global Management LP lifted its position in Vera Therapeutics by 65.2% during the second quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock worth $34,371,000 after buying an additional 375,000 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.